Literature DB >> 22493325

All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration.

Charlotte Lewden, Vincent Bouteloup, Stéphane De Wit, Caroline Sabin, Amanda Mocroft, Jan Christian Wasmuth, Ard van Sighem, Ole Kirk, Niels Obel, George Panos, Jade Ghosn, François Dabis, Murielle Mary-Krause, Catherine Leport, Santiago Perez-Hoyos, Paz Sobrino-Vegas, Christoph Stephan, Antonella Castagna, Andrea Antinori, Antonella d'Arminio Monforte, Carlo Torti, Cristina Mussini, Virginia Isern, Alexandra Calmy, Ramón Teira, Matthias Egger, Jesper Grarup, Geneviève Chêne.   

Abstract

BACKGROUND: Using data from a large European collaborative study, we aimed to identify the circumstances in which treated HIV-infected individuals will experience similar mortality rates to those of the general population.
METHODS: Adults were eligible if they initiated combination anti-retroviral treatment (cART) between 1998 and 2008 and had one prior CD4 measurement within 6 months. Standardized mortality ratios (SMRs) and excess mortality rates compared with the general population were estimated using Poisson regression. Periods of follow-up were classified according to the current CD4 count.
RESULTS: Of the 80 642 individuals, 70% were men, 16% were injecting drug users (IDUs), the median age was 37 years, median CD4 count 225/mm(3) at cART initiation and median follow-up was 3.5 years. The overall mortality rate was 1.2/100 person-years (PY) (men: 1.3, women: 0.9), 4.2 times as high as that in the general population (SMR for men: 3.8, for women: 7.4). Among 35 316 individuals with a CD4 count ≥500/mm(3), the mortality rate was 0.37/100 PY (SMR 1.5); mortality rates were similar to those of the general population in non-IDU men [SMR 0.9, 95% confidence interval (95% CI) 0.7-1.3] and, after 3 years, in women (SMR 1.1, 95% CI 0.7-1.7). Mortality rates in IDUs remained elevated, though a trend to decrease with longer durations with high CD4 count was seen. A prior AIDS diagnosis was associated with higher mortality.
CONCLUSIONS: Mortality patterns in most non-IDU HIV-infected individuals with high CD4 counts on cART are similar to those in the general population. The persistent role of a prior AIDS diagnosis underlines the importance of early diagnosis of HIV infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22493325     DOI: 10.1093/ije/dyr164

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  88 in total

1.  Commentary: can mortality rates among adult antiretroviral therapy patients in Europe reach levels similar to those experienced in the general population?

Authors:  Andrew F Auld; Tedd V Ellerbrock
Journal:  Int J Epidemiol       Date:  2012-03-06       Impact factor: 7.196

Review 2.  Recent Insights Into Cardiovascular Disease (CVD) Risk Among HIV-Infected Adults.

Authors:  Robert C Kaplan; David B Hanna; Jorge R Kizer
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

3.  Are HIV-infected men vulnerable to prostate cancer treatment disparities?

Authors:  Adam B Murphy; Ramona Bhatia; Iman K Martin; David A Klein; Courtney M P Hollowell; Yaw Nyame; Elodi Dielubanza; Chad Achenbach; Rick A Kittles
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-07-25       Impact factor: 4.254

4.  Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection.

Authors:  Peter W Hunt; Elizabeth Sinclair; Benigno Rodriguez; Carey Shive; Brian Clagett; Nicholas Funderburg; Janet Robinson; Yong Huang; Lorrie Epling; Jeffrey N Martin; Steven G Deeks; Curtis L Meinert; Mark L Van Natta; Douglas A Jabs; Michael M Lederman
Journal:  J Infect Dis       Date:  2014-04-21       Impact factor: 5.226

Review 5.  Aging and Neurocognitive Functioning in HIV-Infected Women: a Review of the Literature Involving the Women's Interagency HIV Study.

Authors:  David E Vance; Leah H Rubin; Victor Valcour; Drenna Waldrop-Valverde; Pauline M Maki
Journal:  Curr HIV/AIDS Rep       Date:  2016-12       Impact factor: 5.071

6.  Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration.

Authors:  Delphine Gabillard; Charlotte Lewden; Ibra Ndoye; Raoul Moh; Olivier Segeral; Besigin Tonwe-Gold; Jean-François Etard; Men Pagnaroat; Isabelle Fournier-Nicolle; Serge Eholié; Issouf Konate; Albert Minga; Eitel Mpoudi-Ngole; Sinata Koulla-Shiro; Djimon Marcel Zannou; Xavier Anglaret; Christian Laurent
Journal:  J Acquir Immune Defic Syndr       Date:  2013-04-15       Impact factor: 3.731

7.  Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran.

Authors:  Parag Kumar; Lori A Gordon; Kristina M Brooks; Jomy M George; Anela Kellogg; Maryellen McManus; Raul M Alfaro; Khanh Nghiem; Jay Lozier; Colleen Hadigan; Scott R Penzak
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

8.  Hypertension Among Persons Living With HIV in Medical Care in the United States-Medical Monitoring Project, 2013-2014.

Authors:  Oluwatosin Olaiya; John Weiser; Wen Zhou; Pragna Patel; Heather Bradley
Journal:  Open Forum Infect Dis       Date:  2018-01-30       Impact factor: 3.835

Review 9.  Inflammation, Immune Activation, and Antiretroviral Therapy in HIV.

Authors:  Corrilynn O Hileman; Nicholas T Funderburg
Journal:  Curr HIV/AIDS Rep       Date:  2017-06       Impact factor: 5.071

10.  Determinants of viremia copy-years in people with HIV/AIDS after initiation of antiretroviral therapy.

Authors:  Stephen T Wright; Jennifer Hoy; Brian Mulhall; Catherine C Oʼconnor; Kathy Petoumenos; Timothy Read; Don Smith; Ian Woolley; Mark A Boyd
Journal:  J Acquir Immune Defic Syndr       Date:  2014-05-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.